Abatacept and teriparatide recommended for approval in Japan
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's Orencia (abatacept) and Lilly's Forteo (teriparatide) have been recommended for approval in Japan, for the treatment of rheumatoid arthritis (RA) and osteoporosis, respectively.